Literature DB >> 11520804

Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.

H van der Kuip1, A W Goetz, C Miething, J Duyster, W E Aulitzky.   

Abstract

The phenotype of Bcr-Abl-transformed cells is characterized by a growth factor-independent survival and a reduced susceptibility to apoptosis. Furthermore, Bcr-Abl kinase alters adhesion features by phosphorylating cytoskeletal and/or signaling proteins important for integrin function. Integrin-mediated adhesion to extracellular matrix molecules is critical for the regulation of growth and apoptosis. However, effects of integrin signaling on regulation of apoptosis in cells expressing Bcr-Abl are largely unknown. The influence of adhesion on survival and apoptosis in Bcr-Abl+ and Bcr-Abl- BaF3 cells was investigated. p185bcr-abl-transfected BaF3 cells preadhered to immobilized fibronectin had a significant survival advantage and reduced susceptibility to apoptosis following gamma-irradiation when compared with the same cells grown on laminin, on polylysin, or in suspension. Both inhibition of Bcr-Abl kinase by STI571 and inhibition of specific adhesion reversed the fibronectin-mediated antiapoptotic effect in BaF3p185. The DNA damage response of Bcr-Abl- BaF3 cells was not affected by adhesion to fibronectin. In contrast to parental BaF3 cells, BaF3p185 adherent to fibronectin did not release cytochrome c to the cytosol following irradiation. The fibronectin-mediated antiapoptotic mechanism in Bcr-Abl-active cells was not mediated by overexpression of Bcl-XL or Bcl-2 but required an active phosphatidylinositol 3-kinase (PI-3K). Kinase-active Bcr-Abl in combination with fibronectin-induced integrin signaling led to a hyperphosphorylation of AKT. Thus, cooperative activation of PI-3K/AKT by Bcr-Abl and integrins causes synergistic protection of Bcr-Abl+ cells from DNA damage-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520804     DOI: 10.1182/blood.v98.5.1532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.

Authors:  Stéphane Larochelle; Karl A Merrick; Marie-Emilie Terret; Lara Wohlbold; Nora M Barboza; Chao Zhang; Kevan M Shokat; Prasad V Jallepalli; Robert P Fisher
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

2.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Authors:  Bin Zhang; Min Li; Tinisha McDonald; Tessa L Holyoake; Randall T Moon; Dario Campana; Leonard Shultz; Ravi Bhatia
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

3.  p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.

Authors:  Matthias Gutekunst; Moshe Oren; Andrea Weilbacher; Michael A Dengler; Christiane Markwardt; Jürgen Thomale; Walter E Aulitzky; Heiko van der Kuip
Journal:  PLoS One       Date:  2011-04-21       Impact factor: 3.240

4.  Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.

Authors:  Michael A Dengler; Annette M Staiger; Matthias Gutekunst; Ute Hofmann; Malgorzata Doszczak; Peter Scheurich; Matthias Schwab; Walter E Aulitzky; Heiko van der Kuip
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

5.  Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.

Authors:  T-M Kim; S-A Ha; H K Kim; J Yoo; S Kim; S-H Yim; S-H Jung; D-W Kim; Y-J Chung; J W Kim
Journal:  Blood Cancer J       Date:  2011-08-26       Impact factor: 11.037

6.  Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity.

Authors:  N L Pannucci; D Li; S Sahay; E K Thomas; R Chen; I Tala; T Hu; B T Ciccarelli; N J Megjugorac; H C Adams Iii; P L Rodriguez; E R Fitzpatrick; D Lagunoff; D A Williams; I P Whitehead
Journal:  Blood Cancer J       Date:  2013-08-16       Impact factor: 11.037

7.  Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.

Authors:  M A Dengler; A Weilbacher; M Gutekunst; A M Staiger; M C Vöhringer; H Horn; G Ott; W E Aulitzky; H van der Kuip
Journal:  Cell Death Dis       Date:  2014-01-23       Impact factor: 8.469

8.  Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Authors:  Maike Sonnenberg; Heiko van der Kuip; Silke Haubeis; Peter Fritz; Werner Schroth; Godehard Friedel; Wolfgang Simon; Thomas E Mürdter; Walter E Aulitzky
Journal:  BMC Cancer       Date:  2008-12-11       Impact factor: 4.430

9.  BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.

Authors:  Xuefen Xu; Xiaobo Zhang; Yicheng Liu; Lin Yang; Shaoliang Huang; Lu Lu; Shuhao Wang; Qinglong Guo; Li Zhao
Journal:  Oncotarget       Date:  2016-04-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.